Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Sirius XM Holdings Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while Sirius XM Holdings Inc trades at $28.56 (market cap $9.70B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock and Sirius XM Holdings Inc are close in size by market cap, and Sirius XM Holdings Inc pays a 3.75% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | SIRI | |
|---|---|---|
Market Cap | $9.43B | $9.70B |
Sector | Health | Media |
52-Week High | $356.25 | $32.59 |
52-Week Low | $241.71 | $19.92 |
Enterprise Value | $9.18B | $18.98B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SIRI trades at $28.78, down 3.78% today, reflecting a bearish technical signal amid mixed earnings. The stock shows modest revenue growth and strong cash flow, with a P/E of 11.56 and P/B of 0.81 indicating potential undervaluation. Recent Q2 2026 earnings missed estimates, but the company raised full-year guidance, highlighting stable subscriber metrics and a dividend payout.
The outlook is cautiously optimistic, supported by analyst consensus of $33.17 price target and 58% buy ratings. Key risks include competitive pressures in satellite radio and high debt levels, though declining leverage and share buybacks offer upside. Investors should weigh stable cash generation against growth challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
